Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2013, Article ID 584634, 10 pages
http://dx.doi.org/10.1155/2013/584634
Research Article

Inhibition of LXR /SREBP-1c-Mediated Hepatic Steatosis by Jiang-Zhi Granule

1Institute of Digestive Disease, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China
2Center of Chinese Medicine Therapy and Systems Biology, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
3E-Institute of Shanghai Municipal Education Commission, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China

Received 3 January 2013; Accepted 22 April 2013

Academic Editor: Rong Zeng

Copyright © 2013 Miao Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Chitturi, G. C. Farrell, and J. George, “Non-alcoholic steatohepatitis in the Asia-Pacific region: future shock?” Journal of Gastroenterology and Hepatology, vol. 19, no. 4, pp. 368–374, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Bellentani and M. Marino, “Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD),” Annals of Hepatology, vol. 8, supplement 1, pp. S4–S8, 2009. View at Google Scholar · View at Scopus
  3. H. Zhang, S. M. He, J. Sun et al., “Prevalence and etiology of abnormal liver tests in an adult population in Jilin, China,” International Journal of Medical Sciences, vol. 8, no. 3, pp. 254–262, 2011. View at Google Scholar
  4. S. H. Chen, F. He, H. L. Zhou, H. R. Wu, C. Xia, and Y. M. Li, “Relationship between nonalcoholic fatty liver disease and metabolic syndrome,” Journal of Digestive Diseases, vol. 12, no. 2, pp. 25–130, 2011. View at Google Scholar
  5. M. R. Teli, O. F. W. James, A. D. Burt, M. K. Bennett, and C. P. Day, “The natural history of nonalcoholic fatty liver: a follow-up study,” Hepatology, vol. 22, no. 6, pp. 1714–1719, 1995. View at Google Scholar · View at Scopus
  6. P. Angulo, “Nonalcoholic fatty liver disease,” The New England Journal of Medicine, vol. 346, no. 16, pp. 1221–1231, 2002. View at Google Scholar
  7. H. F. Wei and G. Ji, “Systematic review of treating nonalcoholic fatty liver with taking TCM orally: a clinical randomized controlled trial,” China Journal of Traditional Chinese Medicine and Pharmacy, vol. 27, no. 5, pp. 1309–1314, 2012. View at Google Scholar
  8. H. F. Wei, T. Liu, L. J. Xing, P. Y. Zheng, and G. Ji, “Distribution pattern of traditional Chinese medicine syndromes in 793 patients with fatty liver disease,” Journal of Chinese Integrative Medicine, vol. 7, no. 5, pp. 411–417, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. Y. L. Lu, M. Wang, L. Zhang et al., “Simultaneous determination of six components in the ‘Jiang-Zhi’ Granule by UPLC-MS analysis,” Chinese Journal of Natural Medicines, vol. 8, no. 6, pp. 449–455, 2010. View at Google Scholar
  10. Z. S. Ma, T. Liu, P. Y. Zheng et al., “Effect of Chinese medicine Jiangzhi granula on hepaticlipid of nonalcoholic fatty liver disease rats,” Chinese Archives of Traditional Chinese Medicine, vol. 25, no. 4, pp. 942–944, 2007. View at Google Scholar
  11. J. Folch, M. Lees, and G. H. Slane Stanley, “A simple method for the isolation and purification of total lipides from animal tissues,” The Journal of Biological Chemistry, vol. 226, no. 1, pp. 497–509, 1957. View at Google Scholar · View at Scopus
  12. K. G. Park, A. K. Min, E. H. Koh et al., “Alpha-lipoic acid decreases hepatic lipogenesis through adenosine monophosphate-activated protein kinase (AMPK)-dependent and AMPK-independent pathways,” Hepatology, vol. 48, no. 5, pp. 1477–1486, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. Y. T. Kuo, T. H. Lin, W. L. Chen, and H. M. Lee, “Alpha-lipoic acid induces adipose triglyceride lipase expression and decreases intracellular lipid accumulation in HepG2 cells,” European Journal of Pharmacology, vol. 692, no. 1–3, pp. 10–18, 2012. View at Google Scholar
  14. W. Cui, M. Wang, H. Maegawa et al., “Inhibition of the activation of hepatic stellate cells by arundic acid via the induction of cytoglobin,” Biochemical and Biophysical Research Communications, vol. 425, no. 3, pp. 642–648, 2012. View at Google Scholar
  15. Z. J. Xu, J. G. Fan, X. D. Ding, L. Qiao, and G. L. Wang, “Characterization of high-fat, diet-induced, non-alcoholic steatohepatitis with fibrosis in rats,” Digestive Diseases and Sciences, vol. 55, no. 4, pp. 931–940, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. J. R. Schultz, H. Tu, A. Luk et al., “Role of LXRs in control of lipogenesis,” Genes and Development, vol. 14, no. 22, pp. 2831–2838, 2000. View at Publisher · View at Google Scholar · View at Scopus
  17. Z. L. Ai, C. H. Zhu, M. Min et al., “The role of hepatic liver X receptor alpha- and sterol regulatory element binding protein-1c-mediated lipid disorder in the pathogenesis of non-alcoholic steatohepatitis in rats,” Journal of International Medical Research, vol. 39, no. 4, pp. 1219–1229, 2011. View at Google Scholar
  18. X. Chen, C. Zhang, M. Zhao et al., “Melatonin alleviates lipopolysaccharide-induced hepatic SREBP-1c activation and lipid accumulation in mice,” Journal of Pineal Research, vol. 51, no. 4, pp. 416–425, 2011. View at Google Scholar
  19. Y. Wang, F. Catana, Y. Yang, R. Roderick, and R. B. Van Breemen, “An LC-MS method for analyzing total resveratrol in grape juice, cranberry juice, and in wine,” Journal of Agricultural and Food Chemistry, vol. 50, no. 3, pp. 431–435, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Du, J. S. You, X. Zhao, J. Y. Park, S. H. Kim, and K. J. Chang, “Antiobesity and hypolipidemic effects of lotus leaf hot water extract with taurine supplementation in rats fed a high fat diet,” Journal of Biomedical Science, vol. 17, no. 1, article S42, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. W. Xie, Y. Zhao, and L. Du, “Emerging approaches of traditional Chinese medicine formulas for the treatment of hyperlipidemia,” Journal of Ethnopharmacology, vol. 140, no. 2, pp. 345–367, 2012. View at Google Scholar
  22. M. Wang, T. Liu, H. F. Wei et al., “Clinical study of “Jiang zhi Granule” and behavioral intervention for nonalcoholic fatty liver disease of phlegm and blood-stasis syndrome,” Shanghai Zhong Yi Yao Za Zhi, vol. 44, no. 4, pp. 11–13, 2010. View at Google Scholar
  23. Fatty Liver and Alcoholic Liver Disease Study Group of the Chinese Liver Disease Association, “Guidelines for diagnosis and treatment of nonalcoholic fatty liver diseases,” Chinese Journal of Hepatology, vol. 14, no. 3, pp. 161–163, 2006. View at Google Scholar
  24. V. E. de Meijer, H. D. Le, J. A. Meisel et al., “Dietary fat intake promotes the development of hepatic steatosis independently from excess caloric consumption in a murine model,” Metabolism, vol. 59, no. 8, pp. 1092–1105, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Lin, R. Yang, P. T. Tarr et al., “Hyperlipidemic effects of dietary saturated fats mediated through PGC-1β coactivation of SREBP,” Cell, vol. 120, no. 2, pp. 261–273, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. M. T. Flowers and J. M. Ntambi, “Role of stearoyl-coenzyme A desaturase in regulating lipid metabolism,” Current Opinion in Lipidology, vol. 19, no. 3, pp. 248–256, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. H. X. Guo, D. H. Liu, Y. Ma et al., “Long-term baicalin administration ameliorates metabolic disorders and hepatic steatosis in rats given a high-fat diet,” Acta Pharmacologica Sinica, vol. 30, no. 11, pp. 1505–1512, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. N. Higuchi, M. Kato, Y. Shundo et al., “Liver X receptor in cooperation with SREBP-1c is a major lipid synthesis regulator in nonalcoholic fatty liver disease,” Hepatology Research, vol. 38, no. 11, pp. 1122–1129, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. N. Zelcer and P. Tontonoz, “Liver X receptors as integrators of metabolic and inflammatory signaling,” Journal of Clinical Investigation, vol. 116, no. 3, pp. 607–614, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. S. B. Joseph, A. Castrillo, B. A. Laffitte, D. J. Mangelsdorf, and P. Tontonoz, “Reciprocal regulation of inflammation and lipid metabolism by liver X receptors,” Nature Medicine, vol. 9, no. 2, pp. 213–219, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Grefhorst, B. M. Elzinga, P. J. Voshol et al., “Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles,” Journal of Biological Chemistry, vol. 277, no. 37, pp. 34182–34190, 2002. View at Publisher · View at Google Scholar · View at Scopus
  32. A. I. Shulman and D. J. Mangelsdorf, “Retinoid X receptor heterodimers in the metabolic syndrome,” The New England Journal of Medicine, vol. 353, no. 6, pp. 604–615, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. D. J. Peet, S. D. Turley, W. Ma et al., “Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXRα,” Cell, vol. 93, no. 5, pp. 693–704, 1998. View at Publisher · View at Google Scholar · View at Scopus
  34. H. Basciano, A. Miller, C. Baker, M. Naples, and K. Adeli, “LXRα activation perturbs hepatic insulin signaling and stimulates production of apolipoprotein B-containing lipoproteins,” The American Journal of Physiology, vol. 297, no. 2, pp. G323–G332, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. T. C. Otto and M. D. Lane, “Adipose development: from stem cell to adipocyte,” Critical Reviews in Biochemistry and Molecular Biology, vol. 40, no. 4, pp. 229–242, 2005. View at Google Scholar
  36. I. Shimomura, H. Shimano, J. D. Horton, J. L. Goldstein, and M. S. Brown, “Differential expression of exons 1a and 1c in mRNAs for sterol regulatory element binding protein-1 in human and mouse organs and cultured cells,” Journal of Clinical Investigation, vol. 99, no. 5, pp. 838–845, 1997. View at Google Scholar · View at Scopus
  37. L. W. Weber, M. Boll, and A. Stampfl, “Maintaining cholesterol homeostasis: sterol regulatory element-binding proteins,” World Journal of Gastroenterology, vol. 10, no. 21, pp. 3081–3087, 2004. View at Google Scholar · View at Scopus
  38. M. Kohjima, N. Higuchi, M. Kato et al., “SREBP-1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease,” International Journal of Molecular Medicine, vol. 21, no. 4, pp. 507–511, 2008. View at Google Scholar · View at Scopus
  39. L. Madsen, R. K. Petersen, M. B. Sørensen et al., “Adipocyte differentiation of 3T3-L1 preadipocytes is dependent on lipoxygenase activity during the initial stages of the differentiation process,” Biochemical Journal, vol. 375, no. 3, pp. 539–549, 2003. View at Publisher · View at Google Scholar · View at Scopus
  40. H. Shimano, J. D. Horton, R. E. Hammer, I. Shimomura, M. S. Brown, and J. L. Goldstein, “Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a,” Journal of Clinical Investigation, vol. 98, no. 7, pp. 1575–1584, 1996. View at Google Scholar · View at Scopus
  41. M. Sekiya, N. Yahagi, T. Matsuzaka et al., “Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression,” Hepatology, vol. 38, no. 6, pp. 1529–1539, 2003. View at Publisher · View at Google Scholar · View at Scopus